Abstract
Adjuvant chemotherapy, endocrine therapy, and a combination chemo-endocrine therapy have been proven to prolong disease-free survival (DFS) and to reduce mortality in women with operable breast cancer (Bonadonna et al. 1985; Goldhirsch et al. 1986; UK-BCTSC/UICC/WHO 1984). It has been postulated that therapeutic efficacy is related to an increased tumor cell kill by higher doses of cytotoxic drugs (Bonadonna and Valagussa 1981) or by the selection of patients whose tumors are more responsive to a given treatment (e.g. patients with estrogen-receptor(ER)-positive tumors, who are receiving adjuvant endocrine therapy) (Ludwig Breast Cancer Study Group 1984). The use of sequential non-cross-resistant combinations also appears to enhance effectiveness (Perloff et al. 1986).
For the Ludwig Breast Cancer Study Group (see Appendix A).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 30: 10–15
Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Marchini S, Veronesi U (1981) Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes. The Milan Institute experience. In: Salmon SE, Jones SE (eds) Adjuvant Therapy of Cancer III. Grune and Stratton, New York pp 435–444
Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U (1985) Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95–115
Cox DR (1972) Regression models and life tables (with discussion). J Roy Stat Soc B (Methodol) 34: 187–220
Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Zimmermann A, Locher G, Reed R, Golouh R, Sáve-Sóderbergh J, Hollaway L, Russell I, Rudenstam CM (1986) Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58: 2662–2670
DeWyss WD (1972) Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 32: 374–379
Fisher B, Slack NH, Katrych D, Wolmark N (1975) Ten years of follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528–534
Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488–1492
Fisher B, Redmond C, Brown A, Fischer ER, Wolmark N, Bowman D, Plotkin D, Walter J, Borstein R, Legault-Poisson S, Saffer EA (1986) Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 4: 459–471
Fisher B, Brown A, Wolmark N (1987) Prolonging tamoxifen therapy for primary breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial. Ann Intern Med 106: 649–654
Gelber RD (1985) Methodological and statistical aspects in perioperative chemotherapy trials. In: Metzger U, Largiader F, Senn HJ (eds) Perioperative chemotherapy. Springer, Berlin Heidelberg New York, pp 53–63 (Recent results in cancer research, vol 98 )
Gelber RD, Zelen M (1985) Planning and reporting of clinical trials. In: Calabren P, Rosenberg SA, Schein P (eds) Textbook of medical oncology. MacMillan New York, pp 406–25
Goldie JH, Coldman AJ (1979) A mathematic model of relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733
Goldhirsch A, Gelber RD (1986) Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. NCI Monogr 1: 55–70
Goldhirsch A, Gelber RD, Davis BW (1986) Adjuvant chemotherapy trials in breast cancer: an appraisal and lessons for patient care outside the trials. In: Forbes JF (ed) Breast disease. Clinical Surgery International. Churchill Livingston, Edinburgh, pp 123–138
Goldhirsch A, Gelber RD, Tattersall M, Rudenstam CM, Cavalli F (1987) Methotrexate/ nitrous oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet II: 151
Henderson IC (1987) Adjuvant systemic therapy of early breast cancer. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases. Lippincott, Philadelphia, pp 324–353
Henderson IC, Gelman RS, Harris JR, Canellos GP (1986) Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1: 95–98
Hubay CA, Gordon NH, Crowe JP (1984) Antiestrogen-cytotoxic chemotherapy and bacillus Calmette-Guerin vaccination in stage II breast cancer: seventy-two months’ follow-up. Surgery 96: 61–72
Ingle JN, Everson LK, Wieand HS, Martin JK, Wold LE, Krook JE, Ahman DL, Cullinan SA, Paulsen JK (1986) Randomized trial of adjuvant therapy with cyclophosphamide (C), 5-fluorouracil (F), prednisone (P) with or without tamoxifen (T) vs. observation following mastectomy in postmenopausal women with node-positive breast cancer. Proc Am Soc Clin Oncol 5: 70
Jungi WF, Alberto P, Brunner KW, Cavalli F, Barrelet L, Senn HJ (1981) Short- or long-term adjuvant chemotherapy for breast cancer. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton, New York, pp 395–402
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Ludwig Breast Cancer Study Group (1983) Severe toxicity encountered in adjuvant combination chemotherapy for breast cancer administered in the immediate postmastectomy period. Lancet II: 542–544
Ludwig Breast Cancer Study Group (1984) Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet I: 1256–1260
Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norm T (1978) Surgical adjuvant chemotherapy. Results with one short course of cyclophosphamide after mastectomy for breast cancer. Cancer 41: 2088–2098
Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T (1985) Short perioperative versus long-term adjuvant chemotherapy. In: Metzger U, Largiader F, Senn HJ (eds) Perioperative chemotherapy, Springer, Berlin Heidelberg New York Tokyo pp 91–98 (Recent results in cancer research, vol 98 )
Perloff M, Norton L, Korzan A, Wood W, Carey R, Weinberg V, Holland JF (1986) Advantage of an adriamycin (A) combination plus halotestin (H) after initial cyclophosphamide, methotrexate, fluorouracil, vincristine and prednisone (CMFVP) for adjuvant therapy of node-positive stage II breast cancer. Proc Am Soc Clin Oncol 5: 70
Schabel Jr FM (1977) Rationale for adjuvant chemotherapy. Cancer 39: 2875–2882
Taylor SG, Kalish LA, Olson JE, Cummings F, Bennett JM, Falkson G, Tormey DC, Carbone PP (1985) Adjuvant CMFP vs. CMFP plus tamoxifen vs. observation alone in postmenopausal node-positive breast cancer patients. 3-year results of an ECOG study. J Clin Oncol 3: 144–154
UK-BCTSC/UICC/WHO (1984) Review of mortality results in randomized trials in early breast cancer. Lancet II: 1205
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Goldhirsch, A., Gelber, R.D. (1989). Randomized Perioperative Therapy in Operable Breast Cancer: The Ludwig Trial V. In: Senn, HJ., Goldhirsch, A., Gelber, R.D., Osterwalder, B. (eds) Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research, vol 115. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83337-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-83337-3_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83339-7
Online ISBN: 978-3-642-83337-3
eBook Packages: Springer Book Archive